NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis $5.38 -0.36 (-6.27%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.27▼$5.7250-Day Range$4.45▼$5.9352-Week Range$2.58▼$11.67Volume21,438 shsAverage Volume92,087 shsMarket Capitalization$238.67 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ESSA Pharma alerts: Email Address ESSA Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside206.7% Upside$16.50 Price TargetShort InterestBearish2.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingSelling Shares$12,554 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.71) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector593rd out of 910 stocksPharmaceutical Preparations Industry274th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.32% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 23.6, which indicates bearish sentiment.Change versus previous monthShort interest in ESSA Pharma has recently increased by 3.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 2.5 News and Social Media Coverage News SentimentESSA Pharma has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ESSA Pharma this week, compared to 1 article on an average week.Search Interest4 people have searched for EPIX on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,554.00 in company stock.Percentage Held by Insiders14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.71) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ESSA Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About ESSA Pharma Stock (NASDAQ:EPIX)ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More EPIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPIX Stock News HeadlinesSeptember 4 at 5:01 AM | insidertrades.comESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 SharesSeptember 4 at 5:37 AM | americanbankingnews.comESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 Shares of StockSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 30, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on ESSA Pharma (EPIX)August 8, 2024 | msn.comEPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024…August 5, 2024 | prnewswire.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024July 8, 2024 | prnewswire.comESSA Pharma to Present at the JonesHealthcare Seaside SummitMay 30, 2024 | prnewswire.comESSA Pharma to Present at the Jefferies Global Healthcare ConferenceSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …May 21, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$709.0k On ESSA PharmaMay 14, 2024 | markets.businessinsider.comBuy Rating Endorsed for ESSA Pharma on Robust Pipeline and Market Expansion PotentialMay 14, 2024 | prnewswire.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024April 9, 2024 | finance.yahoo.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | prnewswire.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its BusinessApril 7, 2024 | investing.comEssa Pharma COO sells shares worth over $5,500April 5, 2024 | morningstar.comESSA Pharma Inc EPIXMarch 10, 2024 | finance.yahoo.comEPIX Jul 2024 7.500 callSee More Headlines Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Fiscal Year End9/30/2024Next Earnings (Estimated)12/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+206.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.17% Return on Assets-19.62% Debt Debt-to-Equity RatioN/A Current Ratio36.95 Quick Ratio36.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book1.86Miscellaneous Outstanding Shares44,363,000Free Float37,842,000Market Cap$238.67 million OptionableOptionable Beta1.82 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. David Ross Parkinson M.D. (Age 74)President, CEO & Director Comp: $814.15kMr. David S. Wood C.M.A. (Age 67)CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer Comp: $590.39kMr. Peter A. Virsik M.B.A. (Age 53)M.S., Executive VP & COO Comp: $645.95kDr. Alessandra Cesano M.D. (Age 63)Ph.D., Chief Medical Officer & Executive VP Comp: $623.93kChandtip ChandhasinExecutiveErica OsbourneExecutiveErin RudsinskiExecutiveLoleta HarrisExecutiveNeil ThaparExecutiveNkengyal BarberExecutiveMore ExecutivesKey CompetitorsAnaptysBioNASDAQ:ANABAligos TherapeuticsNASDAQ:ALGSArriVent BioPharmaNASDAQ:AVBPPraxis Precision MedicinesNASDAQ:PRAXEvolusNASDAQ:EOLSView All CompetitorsInsidersPeter VirsikSold 2,082 sharesTotal: $12,554.46 ($6.03/share)Peter VirsikSold 694 sharesTotal: $4,823.30 ($6.95/share)Peter VirsikSold 694 sharesTotal: $5,510.36 ($7.94/share)Peter VirsikSold 694 sharesTotal: $6,232.12 ($8.98/share)Peter VirsikSold 1,718 sharesTotal: $17,197.18 ($10.01/share)View All Insider Transactions EPIX Stock Analysis - Frequently Asked Questions How have EPIX shares performed this year? ESSA Pharma's stock was trading at $6.60 at the beginning of 2024. Since then, EPIX stock has decreased by 18.5% and is now trading at $5.38. View the best growth stocks for 2024 here. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) posted its earnings results on Monday, August, 5th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX). This page (NASDAQ:EPIX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
